Results 91 to 100 of about 811,174 (190)

Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors

open access: yes
Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor-resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown.
Jahan Rahman   +75 more
core   +1 more source

Abstract 3232: Development of novel Btk inhibitor, CB988 targering ibrutinib-resistant Btk C481S mutant

open access: yes, 2017
Introduction: Bruton's tyrosine kinase (Btk) is a member of the Tec family of cytoplasmic tyrosine kinase. Btk plays a crucial role in the BCR signaling, essential for B-cell development, and Btk has been recognized as a validated therapeutic target for ...
Wataru Kawahata   +5 more
core   +1 more source

A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity.
Steven M. Bair   +11 more
wiley   +1 more source

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders

open access: yesBiomolecules
BTK (Bruton’s tyrosine kinase) has become a key therapeutic target across several hematologic diseases, beginning with its original use in CLL/SLL.
Andrea Duminuco   +9 more
doaj   +1 more source

Bioremediation of Chlorpyrifos Contaminated Soil: Microcosm Investigation and 16S rRNA Gene Amplicon Sequencing

open access: yesEnvironmental Microbiology Reports, Volume 18, Issue 6, December 2026.
This study characterized biofilm‐forming bacterial strains Pseudomonas aeruginosa MD3 and Bacillus toyonensis LD07 immobilized on sugarcane bagasse. This highly porous bio‐product demonstrated exceptional phenotypic plasticity and robust bioremediation efficacy, achieving 99% chlorpyrifos degradation at 4500 ppm.
Le Thi Nhi‐Cong   +6 more
wiley   +1 more source

Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging

open access: yesKinases and Phosphatases
Bruton’s tyrosine kinase (BTK) is a key signaling molecule involved in both hematological malignancies and solid tumors. In B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), BTK mediates B-cell receptor ...
Zahraa Qusairy, Miran Rada
doaj   +1 more source

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1541-1551, December 2026.
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao   +4 more
wiley   +1 more source

Challenging Host Specificity: Malacosporean Parasite Dynamics—Tetracapsuloides bryosalmonae Beyond Salmonids—An Infection Experiment

open access: yesJournal of Fish Diseases, Volume 49, Issue 12, December 2026.
ABSTRACT Proliferative Kidney Disease (PKD) is a severe parasitic disease of salmonids caused by the malacosporean endoparasite Tetracapsuloides bryosalmonae. In the fish intermediate host, the parasite is disseminated via the circulatory system and ultimately reaches the kidney, where it matures before releasing infective spores into the environment ...
Céline Möckli   +4 more
wiley   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2741-2763, November 2026.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting

open access: yesJournal of Hematology & Oncology
Although covalent and non-covalent Bruton tyrosine kinase inhibitors (BTKi) have extended clinical benefit to relapsed/refractory (R/R) and BTKi-resistant chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), there remains an unmet need for ...
Pritika Sharma, Heng Jiang, Delong Liu
doaj   +1 more source

Home - About - Disclaimer - Privacy